MilliporeSigma, 10x Genomics Launch New Option For CRISPR Research

June 10, 2020

By Bio-IT World Staff

June 10, 2020 | MilliporeSigma and 10x Genomics announced that they have developed a new option for biological experiments. The collaboration provides a linking of two innovative technologies: single cell transcriptomics and pooled CRISPR screening.

The first commercially offered, ready-to-use tool enables simultaneous measurement of gene perturbation and unbiased gene expression from single cells. MilliporeSigma provides fully tested and validated reagents and workflows to run single-cell screening on 10x Genomics’ platform.

“Researchers today require more detailed information to better understand the relationship between specific genes and disease,” Andrew Bulpin, head of Process Solutions at MilliporeSigma, said in a press release. “Our genome-editing technology, combined with 10x Genomics’ Feature Barcode technology, will allow researchers to screen single cells using CRISPR libraries. These insights can lead to the identification of novel molecular therapeutic targets and accelerate drug discovery in immuno-oncology, autoimmunity, neurodegeneration and other human diseases.”

The companies will work together as part of 10x Genomics’ 10x Compatible Partnership Program, a global ecosystem of technologies and solutions that provide customers with the ability to enhance their unique research applications and accelerate discovery. This program has established a broad coalition of technology platforms that together span all aspects of the next-generation sequencing workflow, from sample prep to informatics. The two companies’ combined technologies developed under the 10x Compatible Product Partnership Program are  expected to deliver a greater potential for enabling scientific discovery.

“CRISPR-based screening allows researchers to isolate a set of genes and identify their potential as targets for a therapeutic. But, if these experiments are done in bulk, the phenotypes are difficult, or impossible, to resolve,” said Michael Schnall-Levin, senior vice president of R&D and founding scientist at 10x Genomics, in an official statement. “When combined with single cell transcriptomics, each phenotype can be isolated and fully profiled using its gene expression patterns, creating a dynamic view of the genes driving the phenotype and morphology to better understand the underlying biology.”